The nature of alloantigens seen by T lymphocytes, in particular the role of peptides in allorecognition, has been studied intensively whereas knowledge about the in vivo emergence, diversity, and the structural basis of specificity of alloreactive T cells is very limited. Here we describe human T cell clones that recognize HLA-B35 alloantigens in a peptide-dependent manner. TCR sequence analysis revealed that several of these allospecific clones utilize homologous TCR: they all express TCRAV2S3J36C1 and TCRBV4S1J2S7C2 chains with highly related CDR3 sequences. Thus peptide-specific alloreactivity is reflected in homologous CDR3 sequences in a manner similar to that described for T cells that recognize nominal peptide/self-MHC complexes. The in vivo frequency of this TCR specificity was studied in unstimulated PBL of the responding cell donor who was not sensitized against HLA-B35. The vast majority (,'o75%) of the VA2S3J36 junctional regions obtained from two samples of PBL, isolated at a 9-yr interval, encode CDR3 identical or homologous to those of the functionally characterized HLA-B35 allospecific T cells. These data are most easily explained by a model of alloreactivity in which persistent or recurrent exposure to a foreign peptide/self-MHC complex led to the in vivo expansion and long-term maintenance of specific T cells that show fortuitous crossrecognition of an HLA-B35/peptide complex and dominate the alloresponse against HLA-B35.
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Summary
The nature of alloantigens seen by T lymphocytes, in particular the role of peptides in allorecognition, has been studied intensively whereas knowledge about the in vivo emergence, diversity, and the structural basis of specificity of alloreactive T cells is very limited. Here we describe human T cell clones that recognize HLA-B35 alloantigens in a peptide-dependent manner. TCR sequence analysis revealed that several of these allospecific clones utilize homologous TCR: they all express TCRAV2S3J36C1 and TCRBV4S1J2S7C2 chains with highly related CDR3 sequences. Thus peptide-specific alloreactivity is reflected in homologous CDR3 sequences in a manner similar to that described for T cells that recognize nominal peptide/self-MHC complexes. The in vivo frequency of this TCR specificity was studied in unstimulated PBL of the responding cell donor who was not sensitized against HLA-B35. The vast majority (,'o75%) of the VA2S3J36 junctional regions obtained from two samples of PBL, isolated at a 9-yr interval, encode CDR3 identical or homologous to those of the functionally characterized HLA-B35 allospecific T cells. These data are most easily explained by a model of alloreactivity in which persistent or recurrent exposure to a foreign peptide/self-MHC complex led to the in vivo expansion and long-term maintenance of specific T cells that show fortuitous crossrecognition of an HLA-B35/peptide complex and dominate the alloresponse against HLA-B35.
T cell recognition is confined to peptide stretches of antigenic proteins that are selected by binding to polymorphic peptide-binding grooves of MHC class I and class II molecules (1-3). Positive and negative selection steps in the thymus prepare T cells for this task (4) . Self peptides presented by autologous MHC molecules play an essential role in both selection steps (5) . Against this background T cell-mediated alloreactivity remains puzzling since it does not concur with the rules of positive and negative selection: aUoreactive T cells respond to MHC molecules for which they have not been positively selected. Likewise they are not negatively selected against self peptides presented by allogeneic molecules (subsequently referred to as "allo-self complexes"), rather they are specifically reactive for such allo-self complexes (6, 7) . Characterization of T cell clones specific for foreign peptide presented by self MHC and MHC alloantigens demonstrated that alloreactivity is not a function of a particular population of T cells but is an intrinsic property of many T cells (8, 9) and that this dual specificity is accomplished by one TCR (10) . It is assumed that alloreactivity represents fortuitous cross-reactive binding of TCR to particular allo-self complexes but the molecular basis of this cross-reactivity is not yet fully understood (11, 12) .
Insight into the structural basis of alloresponses can be gained by analyzing TCR of alloreactive T cells. A threedimensional model of the TCR proposes that CDR1 and 2, encoded by TCRAV and TCRBV gene segments, interact with the c~-helices of the MHC molecules and the hypervariable CDR3, encoded by V-(D)-Jjunctional regions, contact protruded peptide side chains (13) . Analyses of alloreactive T cells in mice and humans revealed a complex TCR usage and support the hypothesis that an alloresponse is mediated by heterogeneous T cells recognizing a wide variety of alloself complexes (14) (15) (16) (17) .
In contrast, we show here that a group of HLA-B35 specific, peptide-dependent, alloreactive T cells utilize a set of distinct, yet nearly identical TCR. One of these TCR sequences was found to be predominantly expressed in the unstimulated PBL of the donor whose cells were stimulated in vitro to generate the alloreactive T cells. Furthermore, a second of these TCR sequences was detected with high frequency in a PBL sample obtained from this donor nine years later.
Thus, this example of allorecognition represents a case in which an allo-self complex is recognized presumably due to its similarity to a nominal peptide/self-MHC complex that selectively activated and maintained these T cells in vivo over a very long time.
Materials and Methods
Cells. PBL ofheahhy Caucasian donors were HLA typed using local and International Histocompatibility Workshop reagents. HLA-B35 variants were characterized by DNA sequencing (18) . EBV-transformed lyrnphoblastoid cell lines (LCL) 1 were established using culture supernatants of the marmoset cell line producing the B95.8 strain of EBV (American Type Culture Collection, Rockville, MD). LCL or PHA-stimulated PBL were used as target cells for the ceil-mediated lympholysis assay and their complete HLA types are as follows:
GM: A2,B8,B40,Cw7,DK2,DR3; DS: A2,A3,B* 3501,B37,Cw4,Cw6,DR1,DR2; PR: A1,A3,B* 3501,Cw4,DR4,DR13 HF: A1,A3,B" 3503,B38,Cw4,Cw6,DR3,DK13; TL: A2,A24,B13,B*3508,Cw4,Cw6,DK3,DR7; GN: A3,A31,B*3508,B55,Cw3,Cw4,DR4.
The HLA-B'3501 gene was isolated from a genomic library of donor DS. The HLA-A, -B, -C null I_CL 721.221 (19) was obtained from the ATCC and transfected by electroporation with HLA-B*3501 cloned into the pHEBo vector (20) . P815-HTR mastocytoma cells were also transfected with HLA-B*3501 as described elsewhere (21) . T2 is a fusion product of the T-LCL CEM and the LCL721.174 and is MHC hemizygous (22) . The residual class I region encodes HLA-A2, -Cwl, -B51; the class II region has a large deletion including the TAP and LMP genes (23) . Untransfected T2 cells were kindly provided by Dr. R. Tampe (Max-Planck Institute of Biochemistry, Martinsried, Germany); T2 cells transfected with HLA-B'3501 were kindly provided by Dr. M. Takiguchi (Institute of Medical Science, Tokyo, Japan). The cell lines BM28.7 and BM36.1 were generously provided by Dr. A. Ziegler (Institute of Experimental Oncology and Transplantation, Berlin, Germany); they were derived by mutagenesis from the Burkitt's lymphoma line BJAB; BM28.7 is MHC hemizygous and carries only the A1, Cw4, B*3501 haplotype of BJAB. BM36.1 carries a deletion in its TAP2 gene and lacks a functional peptide transporter (24) .
CTL. An FILA-B35-specific CTL line was made by stimulating B35-negative PBL of donor GM, isolated in 1979, with irradiated B*3501-positive lymphocytes of donor DS for 6 d in MI.C. After positive selection of CD8 § lymphocytes using anti-CD8-antibody-coated magnetic beads (Dynal, Hamburg, Germany), cloning was performed by seeding 0.3 cells/well in the presence of rlL-2 (40 U/ml) (Proleukin; Eurocetus, Frankfurt, Germany) and irradiated stimulator cells. The remaining CD8 + lymphocytes were cultivated for several months with irradiated stimulator cells (DS) and rlL-2 (40 U/ml). From this CD8 § line Vc~2.3-bearing T cells were positively selected implementing mAb F1 (T Cell Sciences, Cambridge, MA) in combination with goat anti-mouse IgG antibodies coupled to magnetic beads (M450; Dynal).
i Abbreviations used in this paper: I.CL, lymphoblastoid cell lines; MFI, mean fluorescence intensity.
Cell-mediated Lympholysis Assay. Cytotoxic activity was determined using a standard chromium release assay (25) . A percent cytotoxicity was calculated using the formula: % lysis = ([experimental cpm -spontaneous cpm]/[total cpm -spontaneous cpm]) xl00.
lmmunofluorescence Analysis and Antibodies. Indirect immunofluorescence was made using undiluted hybridoma culture supernatants or ascites (1:1,000) in the first step followed by FITCconjugated goat anti-mouse Ig antibody (F261; Dakopatts, Copenhagen, Denmark). The following antibodies were used: anti-Bw6 (Biotest, Dreieich, Germany) for assessment of HLA-B35; F1 (T Cell Sciences) for detection of Vc~2.3 § T cells; and MPC 11 and UPC 10 (Sigma Chemical Co., St. Louis, MO) as isotype controls. For two-color immunofluorescence cells were incubated with unlabeled primary antibody, washed twice, and stained with PE-labeled rabbit anti-mouse Ig F(ab')2 (Medac, Hamburg, Germany). Free sites were saturated with excess mouse IgG1 and lgG2a (Coulter, Hialeah, FL). Finally the cells were incubated with FITC-conjugated anti-CD8 mAb (Immunotech, Marseille, France). Analyses were carried out on a FACScan | instrument (Becton Dickinson, Mountain View, CA) with gates set to include only living cells.
Analysis of TCR Usage and Determination of TCR Sequences. Total cellular RNA was isolated using RNAzol B (CINNA/BIOTECX, Houston, TX). TCRA and TCRB cDNA of the T cell clones was synthesized using the oligonucleotides Cae and Cfle (26) and of the PBL, the T ceil line and the Va2.3 selected T cells using the oligonucleotides CccST (5' CACTGAAGATCCATCATCTG 3') and C~ST (5' TAGAGGATGGTGGCAGACAG 3') with RAV-2 reverse transcriptase (Amersham Buchler GmbH, Braunschweig, Germany). For the T cell clones PCK was performed from cDNA with five sets of TCRAV (Vul-6/7-12/13-16,23,24/17-22/25-29,32) and four sets of TCRBV family specific oligonucleotides (V~l-4, 5.1,5.2,6/7-12/13.1,13.2,14-18/19-24) in combination with biotinylated oligonucleotides derived from TCRAC (T-Cc~) (27) and TCRBC (3'C3) (28) gene segments, respectively. Oligonucleotides V~I to V~12 with Vcd7 to 21 and V/~I to V320 were synthesized according to published sequences (27, 28) The PCK protocol was as above except that 35 cycles were performed: Amplification products were separated on a 4% NuSieve 3:1 agarose gel (FMC Corp. BioProducts, Rockland, ME) and photographed (Film Type 55; Polaroid, Cambridge, MA). The TCRAV and TCRBV amplicons of the T cell line were directly sequenced as described above. 
Sequencing of TCR
Results
Peptide-dewndency of HLA-B35-specifig Alloreactive T Cells.
The serological specificity HLA-B35 encompasses at least eight different alleles (29) . Previously, we described several B35-specific, alloreactive T cell clones derived from donor GM that exhibited different lysis patterns for target cells expressing molecular subtypes of HLA-B35 (18 To substantiate the assumption that these T cells were peptide-dependent we studied their lysis of two different B'3501 positive target cells having defects in the transport of endogenous peptides (Fig. 1 ). BM36.1 cells are TAP2 mutant derivatives of BM28.7 whose surface expression of en- (Fig. 1) . After several months of culture the CD8 + T cell fraction from which the T cell clones were derived exhibited a pattern of lysis similar to those of clones B, C, and D (Fig. 1) . These data supported the conclusion that the clones as well as this line were B35 specific and peptide dependent.
TCR Sequences of HLA-B35 Alloreactive T Cells. The
TCRct and TCRfl variable regions of the alloreactive T cell clones were sequenced after PCK amplification using familyspecific oligonucleotides (Fig. 2, A and B) . Interestingly, clones B and D utilized nearly identical TCK: both had recombined TCRAV2S3 with TCRAJ36 and TCKBV4S1 with TCRBJ2S7 gene segments. The CDR3 sequences of both TCR chains were also strikingly similar; they were of identical overall length and composed of the same or chemically related amino acids located at the same positions (Fig. 3) . The BV7S2 gene segment used by clone C differs from the published sequence BV7S2 (clone PL4. 19 ) by a silent C to T substitution in the codon for the carboxy-terminal cysteine. Nucleotide stretches corresponding to TCRBD1 and TCRBD2 sequences are underlined. Boxed nudeotides indicate a frameshift at the N/J junction leading to an out of" frame transcript. These sequence data are available from EMBL/GenBank/ DDBJ under accession numbers Z46961 (A) and Z46963 (B).
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Further TCRA sequences detected in the unselected line T G A n N t F F o were an out of frame V5SIJ52C1 transcript, a V7S2J28 sequence with a CDR3 homologous to VA2S3J36 sequences G A N , t F F G (i.e., an aliphatic residue, followed by a basic aliphatic residue, followed by three small nonpolar residues), a sequence v O A N N L F F G using V12S1 like clone C, and a V32S1J21C1 sequence (Fig. 2  A) . Additional TCRB sequences were defined as V6S2J2S7C2,
, V16S1J1S1C1, and V24S1JIS5C1 (Fig. 2 B) . Three of five TCRB sequences characterized in the T cell T G A N N L F F G line used the J2S7 gene segment which is also present in three T cell clones. The VB16S1 and VB24S1 sequences exhibited T G A N N L F F G a unique, common CDR3 that shared the amino acid sequence "DRG" at the same position exclusively encoded by the TCRBD1 gene segment. In both cases BD1 was joined to the TCRBV and TCRBJ gene segments without insertion ea~s7 of additional nucleotides, thus representing so-called fetalv E O v F G PG type TCR (33) .
In Vivo Expansion of HLA-B35 Alloreactive T Cells. TCIk
with rearranged VA2S3J36 and VB4S2J2S7 gene segments and highly related CDR3 were found in three of seven HLAv E o v F G P G B35-specific, alloreactive T cells and one of these was prevalent in the unselected line. To understand how preferential receptor usage arose following allogeneic stimulation we analyzed the diversity of VA2S3J36 TCR in the 1979 PBL sample of donor GM that was used for establishing the alloreactive T cells and in a PBL sample from 1988. Two color immunofluorescence of the PBL samples revealed that 3.4 and 2.0% of the CD8 + cells expressed Va2.3 TCRa chains, respectively (Fig. 4 , E and F). Frequencies of 2-6% were described for VoL2.3/CD8 + T cells in PBL of healthy individuals (34) . For analysis of the VA2S3J36 TCR repertoire we designed a PCR specific for VA2S3J36 rearranged TCR. Single strand chain polymorphism analysis of the PCR products of the two GM samples showed strong distinct bands whereas those of seven other unrelated individuals gave weak bands or smears, as expected for heterogeneous mixtures of TCR having different CDR3 (data not shown). The strong bands of the GM samples indicated a clonal expansion of VA2S3J36 TCR-expressing T cells; therefore "50 cloned VAS3J36 junctional regions were sequenced from each PBL sample. In the 1979 isolate a single sequence identical to the junctional sequence of the CD8 + line was found in the majority of clones (32 of 55) (Fig. 5) . Sequence 2 is identical to that of clone D. No PCR clone was found with the junctional sequence of T cell clone B; however one PCR clone identical in amino acid sequence but differing by five nucleotides in the junctional region was found twice (sequence 3). Four additional sequences encoded identical or highly related CDR3. Since two of them differed from sequence I by only one nucleotide they may represent Taq incorporation error variants. Altogether 41 of 55 junctional sequences (75%) could be grouped into one homology class.
In the second PBL sample, 27 of the 50 clones (54%) had junctional regions identical to clone D (Fig. 5) . Sequence 1, which was dominant in the 1979 sample was found six times (12%). Again, the junctional sequence of clone B was not
In Vivo Expansion of Alloreactive T Cells by an Antigenic Mimic related in sequence. In addition we found an out of frame rearranged TCRBV2JS3C1 for clone D, TCtLAV17J40C1 for clone E, and TCRBVIJ2S4C2 for clone F.
TCR Usage and Sequences of the HLA-B3 5-specifiG Alloreacrive T Cell Line.
We also evaluated the TCtL usage of the CD8+-positive T cell line that was initiated from the same primary MLC as the clones. Repertoire analysis detected five TCRAV (data not shown) and five TCRBV gene segments (Fig. 4 C) , revealing the oligoclonal composition of the line. Direct sequencing of each amplicon resulted in a single, dearly readable sequence even in the V(D)J junctional region (Fig.  2, A and B) , thus the vast majority of sequences comprising each amplicon was derived from a clonal TCR. The T cell line also included TCR composed of VA2S3J36 and VB4S1J2S7 rearrangements like those identified in clones B and D. The CDR3 sequences of each receptor chain exhibited close homology, in terms of length and amino acid composition, to CDR3 ofdones B and D (Fig. 3) . Therefore it seemed likely that the Va2.3 and V34.1 chains were expressed by the same T cell population. To demonstrate this directly we isolated Vo~2.3-bearing T cells from the line via immunomagnetic bead separation. FACScan analysis revealed that 33% of unselected cells bound the Va2.3-specific mAb (Fig. 4 A) ; 98% of the positively selected cells were Vc~2.3 positive (Fig. 4  B) . When tested in CML these T cells showed a lysis pattern like the unseparated line and clones B and D (Fig. I and data  not shown) . PCIk analysis of cDNA prepared from the selected Vo~2.3 § T cells showed that only amplicons for TCRAV2 (data not shown) and TCRBV4 were visible after 35 cycles found but a TCR identical in amino acid but differing in nucleotide sequence (sequence 3) was detected five times (10%). Therefore after nine years the repertoire of VA2S3J36 TCR was still dominated by a particular homology class that represented 76% (38 of 50 clones) of the junctional sequences.
Junctional sequences not belonging to this homology group (sequences 6-23) were diverse in length and amino acid composition. None was found more than three times or in both PBL samples. 10 started with codon AAC encoding asparagine (but none with AAT that also encodes asparagine) indicating that the AAC codon represented the 3' end of the germline TCKAV2S3 sequence, None of these sequences started with a codon for isoleucine, suggesting that the generation of the homologous sequences did not represent a frequent recombinational event but that their dominance in the PBL of GM was due to selection through antigenic stimulation.
Sequencing 50 cloned VB4S1J2S7junctional regions from each PBL sample supported the results of the VA2S3J36 repertoire analysis. In the 1979 isolate we found the VB4SIJ2S7 sequence of the T cell line once ( Fig. 2 B) ; in the 1988 isolate the sequence of clone D was found four times. Both sequences correspond to the clonally expanded VA2S3J36 sequences 509 Steinle et al.
found at the two time points. The remaining VB4SIJ2S7 sequences were neither identical nor homologous to those found in the alloreactive T cells (not shown). TCRBJ2S7 is utilized by 15-20% of all TCRB sequences in peripheral blood (35) whereas TCRAJ36 is rearranged by •0.7% of TCRA sequences (36) . Therefore the peripheral VB4SIJ2S7 repertoire probably encompasses at least 10-fold more TCR than the VA2S3J36 repertoire. This could explain why we only found the TCRB sequence corresponding to the expanded T cell clone prevalent at each time and that the TCRB sequences occurred at much lower frequencies than the TCRA sequences. Although several hundred clones would need to be sequenced to obtain an accurate frequency distribution in the VB4J2S7 repertoire, these initial findings are in agreement with the preferential expansion of the same T cells identified via their VA2S3J36 sequences.
Discussion
The currently favored model of alloreactivity suggests that peptides associated with allogeneic MHC molecules play a critical role in dictating specificity (6, 7) . Functional evidence Boxed nucleotides indicate a frameshift at the N/J junction leading to an out of frame transcript. These sequence data are available from EMBL/GenBank/ DDBJ under accession number Z46962.
supports the peptide-dependency of the HLA-B35-aUospecific T ceils studied here: first, 721.221 LCL transfected with B'3501 were well lysed, whereas murine mastocytoma cells (P815-B'3501) were not recognized (30 (6) (7) (8) (9) (38) (39) (40) . Less experimental data exists on TCR usage in alloresponses. Sequences of MHC class II specific, alloreactive T cell clones were found to be heterogeneous in usage of TCR V and J gene segments and in CDR3 sequence motifs and no simple correlation between sequence and allospecificity could be drawn (14) (15) (16) . One study demonstrated biased usage of TCRBV elements and a nonrandom, but fairly heterogeneous composition of CDR3~ sequences for HLA-B27 specific, alloreactive T cells; whereas TCRot chains exhibited no common features (17) . This type of heterogeneity is expected if many different allo-self complexes induce allogeneic responses.
Our TCR analysis of B35-allospecific T cell clones revealed a contrasting picture. Although usage of different V and J gene segments was detected in this small set of cells, two of six clones were found to express highly related receptors and a third highly related sequence was found as a dominant population in a long-term B35-allospecific T cell line established from the same primary culture from which the T cell clones were derived. These results revealed that a very restricted TCR usage can dominate an alloresponse. This dominance could be explained either by a strong immunogenicity of the peptide/B35 ligand or by a selective in vivo expansion of these particular T cells. Sequencing of VA2S3J36 transcripts of the PBL sample used for generation of these B35 alloreactive T cells revealed that more than 75% of the transcripts belonged to one homologous TCR family including the TCRA sequences of clone D and the CD8 + T cell line.
Although this pattern of TCR usage contrasts with reports of other alloreactive T cells, conserved TCR. usage was described for a xenogenic response of mice to HLA-Cw3 (41) and for antigen specific T cells. For example, TCR specific for influenza peptides presented by HLA class I molecules exhibited dominant usage of certain TCRAV and TCRBV gene segments and highly homologous CDR3 sequences (42, 43) . Strong evidence exists that the CDR3 interact with protruded side chains of the antigenic peptide presented by the MHC molecule (3, 44, 45) . Accordingly, only one or two amino acids of the CDR3, are critically involved in the interaction with one of the peptide side chains. The CDR3a of these B35-associated TCR all have an isoleucine followed by a basic, aliphatic residue and an amino acid with a small noncharged side chain; similarly the CDR3B show a stretch of three conserved amino acids with glutamic acid followed by two glycine residues. These particular arrangements in the CDR3 and similar functional patterns support the contention that these TCR recognize the same or highly related peptides and that their specificity can be attributed to CDR3 sequences in a manner analogous to self MHC-restricted T ceils. For these alloreactive T cells the specificity of the TCR would appear to result from a direct interaction with a peptide presented by B35 and not from an indirect conformational effect of peptide on the MHC molecule. The role of peptide in driving this selection is best exemplified by the finding that from an in vivo pool of VA2S3J36 and VB4J2S7 TCR with rather different CDR3 only those with homologous CDR3 were found among the B35-alloreactive T cells.
The nature of the original stimulus that led to in vivo expansion of these particular T cells remains unknown: the donor was not directly exposed to a B35-associated allogeneic stimulus through transplantation, blood transfusion, or pregnancy. Even stronger clonal expansions of particular CD8 + T cells that dominate a given V/3 family were described for elderly individuals, but their specificity was not characterized (46) . A recent study of Burrows et al. demonstrated that the alloresponse to HLA-B*4402 of HLA-B8, EBV-seropositive individuals is dominated by CTL that recognize an EBNA3-derived peptide presented by HLA-B8; thus a pathogen driven response in vivo can result in a cross-reactive allogeneic response in vitro (47) . EBV transformed B cells of donor GM were not recognized by the HLA-B35-alloreactive T cells (data not shown), although EBV would provide a persistent stimulus in vivo.
The maintenance of oligoclonally expanded, alloreactive T cell populations over long periods could have important implications for transplantation. Acute graft rejection occurring from one week to several months after transplantation is usually considered to be initiated by interactions of T helper and CTL; a restricted V/~ usage was shown for alloreactive T cell lines established from renal allografts during an active phase of rejection (48) . The immunological basis of accelerated (early acute) graft rejection that occurs within days of engraftment is unclear, although it is also thought to be cell mediated (49) . The prevalence of presensitized CTL that mediate alloresponses against a class I mismatched graft may contribute to this practically untreatable form of rejection. If preexpanded T cell populations sharing homologous TCIL cause early acute allograft rejection it may be possible to develop strategies to achieve TCR-specific immunosuppression similar to those utilized in experimental animal models (50).
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